Gilead Sciences, Inc (GILD) Sec Form 10K
Gilead Sciences, Inc (NASDAQ: GILD) Sec Form 10K
Gilead Sciences, Inc (GILD) Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
Gilead Sciences, Inc (NASDAQ: GILD) FY 2026 Other Release
Gilead Sciences, Inc (GILD) Sec Form 8K
Gilead Sciences, Inc (NASDAQ: GILD) Sec Form 8K
Gilead Sciences, Inc (GILD) Barclays Annual Global Healthcare Conference
Gilead Sciences, Inc (NASDAQ: GILD) FY 2026 Corporate Conference
Gilead Sciences, Inc (GILD) Leerink Partners Global Healthcare Conference
Gilead Sciences, Inc (NASDAQ: GILD) FY 2026 Corporate Conference
Gilead Sciences, Inc (GILD) TD Cowen Annual Health Care Conference
Gilead Sciences, Inc (NASDAQ: GILD) FY 2026 Corporate Conference
Analysis
S&P 500 Gains as Risk-On Rotation Sends Energy Up 1.84%, Utilities Down 1.68%
S&P 500 gains 0.52% as energy surges 1.84% and tech adds 1.34%, while utilities tumble 1.68% in risk-on rotation.
Gilead Sciences, Inc (GILD) Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
Gilead Sciences, Inc (NASDAQ: GILD) FY 2026 Other Release
Gilead Sciences, Inc (GILD) Sec Form 8K
Gilead Sciences, Inc (NASDAQ: GILD) Sec Form 8K
AlphaGraphs
Gilead Sciences (GILD) Q4 2025 adj. earnings decline, despite higher revenues
Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, has reported a decline in adjusted earnings for the fourth quarter...